NCT07327164 2026-01-09
Precision Medicine for Neurocutaneous Syndromes in Western China
West China Hospital
Completed
Clinical Trials
11 trialsNCT03108066 2024-09-24
MK-3795-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT00970970 2024-05-06
VHLimage
University Medical Center Groningen
Completed
NCT01967537 2019-11-19
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00062166 2018-11-14
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Completed
NCT02108002 2018-09-14
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00052013 2017-03-06
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Novartis
Phase 2 Completed
NCT00088374 2012-07-27
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00075348 2012-03-15
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Completed
NCT00001668 2008-03-04
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
National Institutes of Health Clinical Center (CC)
Completed
NCT00056199 2008-03-04
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed